March 28, 2017 9:11 PM ET


Company Overview of Polyphor Ltd

Company Overview

Polyphor Ltd., a pharmaceutical company, engages in the discovery and development of macrocycle drugs addressing high unmet medical needs. Its product pipeline includes CXCR4 antagonist POL6326, a potent and selective antagonist of the chemokine receptor CXCR4 that blocks the interaction with the ligand stromal cell-derived factor 1 resulting in the mobilization of stem cells from the bone marrow into the circulating blood; Antibiotic POL7080, a pseudomonas specific antibiotic with a novel mode of action; and Neutrophil elastase inhibitor POL6014, a selective and reversible inhibitor of human neutrophil elastase for the treatment of respiratory diseases, such as chronic obstructive pulmonary...

Hegenheimermattweg 125

Allschwil,  4123


Founded in 1996


41 61 567 16 00


41 61 567 16 01

Key Executives for Polyphor Ltd

Chief Executive Officer
Age: 62
Co-Founder and Chief Scientific Officer
Co-Founder and Director
Chief Financial Officer
Head of the Internal Services
Compensation as of Fiscal Year 2016.

Polyphor Ltd Key Developments

Polyphor Announces Executive Changes

Polyphor has named Dr. Debra Baker as its new chief medical and development officer. The role focuses on clinical strategy and drug development. Dr. Baker arrives at Polyphor from Novartis, where she held several positions including global head of medical affairs, development head for infectious diseases, transplants and immunology, and global head of clinical operations and services. Dr. Baker succeeds Leon Hootftman, who leaves Polyphor to take a new position.

Polyphor Appoints Debra Barker as Chief Medical and Development Officer, Effective May 01, 2017

Polyphor announced the appointment of Dr. Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO). Dr. Barker joins Polyphor effective May 01, 2017. Her significant experience in infectious and respiratory diseases and immunology and her leadership make her the perfect fit and will be instrumental to Polyphor's Pharma business.

Polyphor Ltd. Receives CHF 2.3 Million Award from Wellcome Trust to Accelerate the Development of a Novel Antibiotic Drug Class

Polyphor Ltd. announced that it has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates. These are based on Polyphor's new product class, the Outer Membrane Protein Targeting Antibiotics, which has shown outstanding efficacy against the most resistant strains of Gram-negative pathogens. The Seeding Drug Discovery Award will help support the development of novel antibiotics over the next 18 - 24 months.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Polyphor Ltd, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at